Recent years have seen a notable transformation in medicine. We explore 5 key medical advancements, how they are changing medicine today, and what the future might hold.

Medical advancements have seen a substantial shift in recent years from simply treating disease symptoms to influencing health right down to the molecular level. Coupled with the burgeoning capabilities of AI, we can expect to see progress continue at a speed and scale not seen before.

Below, explore our 5 standout medical developments from the 2020s so far.

Originally developed for cancer, mRNA vaccines may be viewed as one of the most significant technological advances in modern vaccinology. Since they can be produced quicker than other types of vaccines, scientists can act faster than ever before when a new infectious threat emerges.

Though mRNA technology had been in development for years, the COVID-19 vaccine’s quick and successful deployment demonstrated the potential for mRNA vaccines at a scale not previously seen.

Rather than using a live or dead microbe, mRNA vaccines work by giving your cells temporary genetic instructions to produce a small part of the target microbe (known as an antigen).

Using mRNA eliminates the risk of whole microbes which must go through extra safety steps to make sure they can never mutate back into a disease-causing entity.

Additionally, as mRNA vaccines do not require the pathogen to be cultivated (grown) in a lab first, this time-consuming bottleneck that exists with many other vaccine types is mitigated.

The most recent mRNA vaccine to be approved by the FDA is the influenza vaccine.

Though more may be to come, as researchers investigate mRNA vaccines for respiratory syncytial virus, CMV, Epstein-Barr virus, and HIV.

Modern medicine focuses more intently on precise targeting over a “one-size-fits-all” approach.

Under the broad name “precision medicine“, this approach underpins many aspects of the healthcare journey, from risk factor identification to diagnostics to treatment selection.

Multi-omic profiling plays a huge part in precision medicine. This method goes beyond standard genetic testing, combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics to identify changes across multiple biological layers.

Key ‘omic terms:

  • Genomics: Analyzing the genome (all the DNA that make up your cells) to find inherited disease risks and structural variations.
  • Epigenomics: Tracking chemical tags on DNA that turn genes on or off based on lifestyle and environment.
  • Transcriptomics: Reading the real-time RNA messages to see which genes a cell is actively using.
  • Proteomics: The study of the proteome — the entire set of proteins produced by an organism. Certain protein “biomarkers” may indicate disease, and many drugs are made to target specific proteins.
  • Metabolomics: Profiling small-molecule cellular chemicals and cellular by-products left behind by metabolic processes.
  • Microbiomics: Mapping the trillions of microbes inside our bodies that influence immunity and drug metabolism.

Combined with environmental factors, this rich data profile can help healthcare professionals understand a person’s risk of disease and their response to a treatment in real-time.

In recent years, ‘omics technologies have progressed rapidly and look set to continue thanks to AI enabling huge amounts of data to be processed and analyzed across disciplines. This allows for much more tailored treatments that consider multiple factors together.

That’s not to say a drug will be made specifically for an individual — rather, that understanding the molecular characteristics and data profiles of groups of people with a particular condition can help inform the drug development process and identify drugs with the best chance of working for these populations.

Multi ‘omics technologies pull vast amounts of data from easy to collect liquid samples (known as ‘liquid biopsies’), helping diagnose rare diseases and catch conditions much earlier and more easily.

Multi-omic profiling of cancer can identify mutations, track the proteins driving tumor growth, and map where these cells live in 3D tissue via spatial biology. Therapies more likely to kill cancer cells can then be selected with higher precision, reducing standard “trial and error” approaches and resulting in faster and more effective treatment.

Though cancer treatment remains centred on traditional methods like surgery, chemotherapy, and radiation therapy, these methods are increasingly supplemented with harnessing the body’s own immune system to help in the fight against cancer.

One type of cancer immunotherapy in ongoing development is cancer vaccines. These are not preventive vaccines (like the HPV vaccine for example) but therapeutic vaccines, i.e., they help treat existing cancer.

So called “off-the-shelf” cancer vaccines can target either common mutated proteins in cancers (known as shared neoantigens) or tumor-associated antigens (TAAs) — normal proteins that become overexpressed in cancer.

However, an exciting development comes specifically in the field of neoantigen vaccines, where scientist have been working on developing personalized versions of these vaccines.

How neoantigen vaccines work

mRNA is the mechanism typically employed by neoantigen vaccines. Much like mRNA vaccines for viruses, these RNA strands give a person’s cells instructions to create harmless replicas — this time of cancer neoantigens — educating the immune system on what to look for, something akin to a ‘WANTED’ poster.

The immune system is now able to find and kill cancer cells containing this biomarker. Since cancer cells often learn to hide their neoantigens to evade detection, triggering the body to produce large amounts of replica neoantigens forces the immune system to notice and kick into action with the specific target in mind.

Recent trial progress

Many trials have shown promising results in recent years. However, Moderna/Merck’s neoantigen cancer vaccine for recurrent melanoma become the first to meet its endpoint in large phase 3 clinical trials in August 2026.

This key milestone in personalized neoantigen vaccines could unlock vast opportunities across the field of cancer.

Though no neoantigen vaccine is yet FDA-approved (personalized or otherwise), the significant progress in this area offers new hope for the future of cancer treatment.

CRISPR-Cas9 is an intricate molecular system used by bacteria as part of their natural defense system. This mechanism allows bacteria to essentially vaccinate themselves against a microbe using fragments of the invading pathogen itself.

The Cas9 enzyme cuts the invading pathogen’s DNA and the cut parts are woven into a region of the bacteria’s own genome, specifically the CRISPR sequence. When the bacteria next encounters the same pathogen, it can quickly recognize it, locate the matching DNA, and cut this section, killing the invader.

Scientists have harnessed this very system as a precise tool for a type of gene therapy known as gene editing, often likened to a “find-and-replace” system.

In this process, scientists create matching RNA pieces for the specific DNA sequence of interest, such as a faulty gene involved in disease. The RNA fragments then move through the body, locate the target gene, and cut it using the Cas9 enzyme, triggering the cells’ natural repair process. However, this time, when the DNA remakes itself, the faulty gene is instead replaced with the correct genetic sequence.

The use of this molecular system is a revolutionary development, as it allows health care professionals to modify the underlying genetic cause of a condition right at the source.

In 2023, the first cell-based gene therapy using CRISPR-Cas9 therapy, Casgevy, was approved for severe sickle cell disease and transfusion-dependent beta-thalassemia (TDT). So far, these are the only FDA-approved uses.

However, research is ongoing, and CRISPR-Cas9 gene editing could one day have uses in:

GLP-1s for weight loss are nothing new, having been around since the 2010s. However, they saw a substantial surge in popularity following the FDA’s approval of Wegovy (semaglutide) in 2021.

Many other weight loss injections required daily administering, had a poorer side effect profile, and were overall less effective. Though Ozempic (semaglutide) could be prescribed off-label for weight loss, it was not until the higher dose version, Wegovy, took off that Ozempic was propelled into the spotlight — likely spurred on by its use among celebrities when supplies of Wegovy inevitably ran dry.

In fact, the name “Ozempic” became almost synonymous with the entire category of GLP-1s during this time.

Another GLP-1 drug, Mounjaro (tirzepatide), emerged in 2022 with approval for type 2 diabetes (and off-label use for weight loss), quickly followed by Zepbound (tirzepatide), this time with specific FDA-approval for weight loss. Currently undergoing clinical trials is the newest GLP-1 injection, retatrutide, the first of its kind to target three hormone receptors.

In recent years, we’ve also seen developments in the oral forms of GLP-1s.

The latest GLP-1 pill, Foundayo (Orforglipron), was approved in 2026, joining the Wegovy pill approved the previous year. These latest pills are hailed to be more effective for weight loss with fewer side effects than the first-approved GLP-1 pill (Rybelsus) for diabetes (off-label use for weight loss) that came to market in 2019.

However, the initial rush of GLP-1s for weight loss has been somewhat dampened in recent months amidst concerns over possible side effects, instances of misuse, and cosmetic rather than therapeutic motivations for use.

It’s crucial to note that doctors still recommend a holistic approach for weight loss, considering diet, exercise, and other lifestyle factors. Only in certain cases will GLP-1s or other interventions be prescribed in conjunction.

Nevertheless, potential uses of this unique peptide drug could be set to expand even further.

Current research is ongoing to determine how GLP-1s might benefit cardiovascular, kidney, liver, arthritis, and sleep apnea disorders. Mounjaro was the first to be approved by the FDA this year to lower the risk of cardiovascular disease in people with type 2 diabetes at high risk.